The Patent Finder

Merck Sharp & Dohme B.V.

59 patents currently held · Updated Nov 21, 2026
18 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

34
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Crystal Forms of a CCR5 Antagonist (US 10,301,281) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 1 fee due Dec 2, 2026
    The maintenance fee for FSH Receptor Antagonists (US 9,044,463) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
  • 3 fees due Feb 11 to 25, 2027 · next Feb 11
  • 3 fees due Mar 8 to 17, 2027 · next Mar 8
  • 1 fee due May 3, 2027
    The maintenance fee for TSH Receptor Antagonizing Tetrahydroquinoline Compounds (US 9,174,940) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
  • 1 fee due Aug 11, 2027
    The maintenance fee for ANTI-CD27 Antibodies (US 10,556,957) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
  • 2 fees due Sep 22 to 24, 2027 · next Sep 22

Which patents, and when each one lapses · Pro

Recent changes

  • 4 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,618,985Isoquinoline Derivatives
In force
 · High confidence
In forceHigh confidence
US 11,040,184Kit for and Method of Assembling an Applicator for Inserting an Implant
In force
 · High confidence
In forceHigh confidence
US 10,821,277Kit for and Method of Assembling an Applicator for Inserting an Implant
In force
 · Medium confidence
In forceMedium confidence
US 7,820,649Quinazolinone and Isoquinolinone Acetamide Derivatives
In force
 · High confidence
In forceHigh confidence
US 7,906,5042-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE Derivatives
In force
 · Medium confidence
In forceMedium confidence
US 8,722,037X-Ray Visible Drug Delivery Device
In force
 · High confidence
In forceHigh confidence
US 7,820,707Heterocyclic Derivatives
In force
 · High confidence
In forceHigh confidence
US 8,333,983Drug Delivery System
In force
 · High confidence
In forceHigh confidence
US 8,183,228Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label
In force
 · Medium confidence
In forceMedium confidence
US 8,168,595Antithrombotic Dual Inhibitors Comprising a Biotin Residue
In force
 · High confidence
In forceHigh confidence
10 of 59 patents shown.
Pro members see all 59.
Pro members: see all 59 patents
Also on record, not counted in the 59: 18 patents in force now held by others · 50 lapsed for an unpaid fee · 94 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

17 abandoned

Showing 1 to 10 of 17, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
18/541,600Combination Therapies for Treating CancerDec 15, 2023Abandoned
17/984,2424-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES as BTK InhibitorsNov 10, 2022Abandoned
17/469,359Antibodies to Human Programmed Death Receptor PD-1Sep 8, 2021Abandoned
18/043,602Combination Therapy of a PD-1 Antagonist and an Antagonist for VEGFR-2 for Treating Patients with CancerSep 2, 2021Abandoned
17/326,373Kit for and Method of Assembling an Applicator for Inserting an ImplantMay 21, 2021Abandoned
17/142,2024-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES as BTK InhibitorsJan 5, 2021Abandoned
17/426,723Belantamab Mafodotin in Combination with Pembrolizumab for Treating CancerJan 31, 2020Abandoned
16/724,984ANTI-CD27 AntibodiesDec 23, 2019Abandoned
16/336,396ANTI-CD27 AntibodiesSep 25, 2017Abandoned
15/738,404Backstop for a SyringeJun 20, 2016Abandoned
10 of 17 applications shown.
Pro members see all 17 published applications.
Pro members: see all 17 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited